Phathom Pharmaceuticals, Inc.(PHAT)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,083 of 2,961 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
PHAT Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Phathom Pharmaceuticals, Inc. (PHAT), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores PHAT at 40.9/100 on a 32-signal composite quality model, placing it at rank #2,083 of 2,961 stocks — the bottom half of the AI-ranked universe. PHAT scores in the top quartile across revenue growth (99.3). Areas of concern include balance sheet strength (6.5) and profitability (12.6), which score below median versus the broader universe. Shareholder dilution risk is elevated at 11.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Phathom Pharmaceuticals, Inc. reports quarterly revenue of $74.3M, net income of $-17.6M, free cash flow of $-2.0M. Top institutional holders of PHAT by reported 13-F value include Frazier Life Sciences Management, L.P., Medicxi Ventures Management (Jersey) Ltd, BlackRock, based on the most recent SEC filings. PHAT trades on the Nasdaq exchange and files with the SEC under CIK 1783183. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PHAT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Phathom Pharmaceuticals, Inc. directly from SEC EDGAR. Phathom Pharmaceuticals, Inc.'s 13F Pro composite quality score has ranged between 11 and 59 since 2024, currently 40.9 — an improving long-term trajectory across 56 quarterly and live scoring snapshots.
Revenue
Q2 2026
$74.3M
Net Income
Q2 2026
$-17.6M
Free Cash Flow
Q2 2026
$-2.0M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+216.9% YoYNet Income
+33.8% YoYOperating Income
+42.3% YoYEPS (Diluted)
+42.7% YoYTotal Assets
-31.5% YoYTotal Debt
+3.8% YoYOp. Cash Flow
+37.5% YoYFree Cash Flow
+37.4% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $175.1M +216.9% | $55.3M +8001.5% | $682.0K | $0.00 | — | — |
| Net Income | $-221.2M +33.8% | $-334.3M -65.8% | $-201.6M -2.0% | $-197.7M -37.4% | $-143.9M -11.5% | $-129.1M |
| Operating Income | $-160.0M +42.3% | $-277.5M -65.8% | $-167.3M +3.0% | $-172.4M -27.7% | $-135.1M -7.5% | $-125.7M |
| EPS (Diluted) | $-3.03 +42.7% | $-5.29 -34.6% | $-3.93 +22.2% | $-5.05 -29.8% | $-3.89 | — |
| Total Assets | $259.1M -31.5% | $378.3M -8.6% | $413.8M +151.1% | $164.8M -13.0% | $189.4M -35.8% | $295.1M |
| Total Debt | $209.1M +3.8% | $201.4M +46.1% | $137.8M +44.7% | $95.3M +6.2% | $89.7M +65.0% | $54.3M |
| Operating Cash Flow | $-166.8M +37.5% | $-266.8M -93.9% | $-137.6M +6.1% | $-146.5M +1.3% | $-148.5M -113.0% | $-69.7M |
| Free Cash Flow | $-167.0M +37.4% | $-266.9M -91.7% | $-139.2M +5.7% | $-147.6M +0.8% | $-148.8M -110.4% | $-70.7M |
Get alerted when PHAT's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Phathom Pharmaceuticals, Inc. including:
Top Institutional Holders of PHAT
Frazier Life Sciences Management, L.P.
$135.3M12,466,489 shMedicxi Ventures Management (Jersey) Ltd
$81.0M7,464,572 shBlackRock, Inc.
$49.1M4,525,129 shInvesco Ltd.
$43.7M4,029,731 shCarlyle Group Inc.
$37.9M3,496,808 shMILLENNIUM MANAGEMENT LLC
$36.6M3,375,834 shVANGUARD CAPITAL MANAGEMENT LLC
$28.8M2,656,944 shGW&K Investment Management, LLC
$23.5M2,166,838 shFRANKLIN RESOURCES INC
$21.4M1,970,828 shNEA Management Company, LLC
$21.3M1,960,169 sh
| Fund | Value | Shares |
|---|---|---|
| Frazier Life Sciences Management, L.P. | $135.3M | 12,466,489 |
| Medicxi Ventures Management (Jersey) Ltd | $81.0M | 7,464,572 |
| BlackRock, Inc. | $49.1M | 4,525,129 |
| Invesco Ltd. | $43.7M | 4,029,731 |
| Carlyle Group Inc. | $37.9M | 3,496,808 |
| MILLENNIUM MANAGEMENT LLC | $36.6M | 3,375,834 |
| VANGUARD CAPITAL MANAGEMENT LLC | $28.8M | 2,656,944 |
| GW&K Investment Management, LLC | $23.5M | 2,166,838 |
| FRANKLIN RESOURCES INC | $21.4M | 1,970,828 |
| NEA Management Company, LLC | $21.3M | 1,960,169 |
Companies Similar to PHAT
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Vir Biotechnology, Inc.
Orchestra BioMed Holdings, Inc.
BIODESIX INC
Evolus, Inc.
RHYTHM PHARMACEUTICALS, INC.
CG Oncology, Inc.
Invivyd, Inc.
4D Molecular Therapeutics, Inc.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put PHAT on your watchlist
Track score changes the day Phathom Pharmaceuticals, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is PHAT a good stock to buy?
13F Pro's AI-powered analysis of Phathom Pharmaceuticals, Inc. (PHAT) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for PHAT are available on the PHAT stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. PHAT is classified as a small company.
Which hedge funds own PHAT?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling PHAT. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Phathom Pharmaceuticals, Inc.'s investment landscape.